Daiichi Sankyo and ArQule strike oncology alliance
This article was originally published in Scrip
Executive Summary
ArQule has struck another deal with a Japanese company for its lead development project ARQ 197, this time withDaiichi Sankyo, which is to co-develop and commercialise the c-Met receptor tyrosine kinase inhibitor worldwide outside certain Asian markets.